News
DHTRF
12.86
NaN%
--
Canaccord Genuity Remains a Buy on DRI Healthcare (DHT.UN)
TipRanks · 13h ago
Stifel Nicolaus Sticks to Its Buy Rating for DRI Healthcare (DHT.UN)
TipRanks · 13h ago
DRI Healthcare (DHT.UN) Gets a Buy from Stifel Nicolaus
TipRanks · 06/12 17:05
CIBC Sticks to Its Buy Rating for DRI Healthcare (DHT.UN)
TipRanks · 05/19 14:35
DRI Healthcare (DHT.UN) Gets a Buy from Stifel Nicolaus
TipRanks · 05/19 13:55
RBC Capital Remains a Buy on DRI Healthcare (DHT.UN)
TipRanks · 05/19 01:55
DRI Healthcare Trust declares $0.11 dividend
Seeking Alpha · 05/15 13:12
DRI Healthcare Trust reports Q1 results
Seeking Alpha · 05/15 11:10
Stifel Nicolaus Reaffirms Their Buy Rating on DRI Healthcare (DHT.UN)
TipRanks · 05/13 17:35
Stifel Nicolaus Keeps Their Buy Rating on DRI Healthcare (DHT.UN)
TipRanks · 05/06 18:15
Stifel Nicolaus Sticks to Their Buy Rating for DRI Healthcare (DHT.UN)
TipRanks · 04/30 18:06
RBC Capital Reaffirms Their Buy Rating on DRI Healthcare (DHT.UN)
TipRanks · 04/22 02:15
DRI Healthcare Trust price target raised to C$22 from C$21 at Stifel
TipRanks · 04/02 15:25
DRI Healthcare (DHT.UN) Receives a Buy from Stifel Nicolaus
TipRanks · 04/01 14:15
DRI Healthcare Raises US$250 Million in Secured Notes to Refinance Debt and Support Growth
TipRanks · 03/25 18:09
DRI Healthcare Refinances Series C Preferreds With C$108.7 Million Convertible Debenture Issue
TipRanks · 03/21 02:37
Dri Healthcare Earnings Call Highlights Record Margins
TipRanks · 03/08 00:23
RBC Capital Sticks to Its Buy Rating for DRI Healthcare (DHT.UN)
TipRanks · 03/06 01:55
DRI Healthcare Trust price target raised to C$21 from C$20 at Stifel
TipRanks · 03/05 17:10
Stifel Nicolaus Remains a Buy on DRI Healthcare (DHT.UN)
TipRanks · 03/05 15:56
More
Webull provides a variety of real-time DHTRF stock news. You can receive the latest news about DRI HEALTHCARE TRUST through multiple platforms. This information may help you make smarter investment decisions.
About DHTRF
DRI Healthcare Trust is a global pharmaceutical royalty monetization company. The Company's portfolio consists of 29 royalty streams on 23 products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. Its Royalty Assets include Ekterly, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Vonjo I, Vonjo II, Xolair, Zejula, Zytiga, and others. The Ekterly is an oral on-demand therapy for treating attacks associated with Hereditary Angioedema (HAE). The Eylea I is a vascular endothelial growth factor inhibitor initially indicated for the treatment of neovascular wet age-related macular degeneration. Natpara is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.